Global Pulmonary Arterial Hypertension Market Analysis and Forecast Report 2030

$5,000$10,000

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2022 – 2030

Clear

Description

Global Pulmonary Arterial Hypertension Market Analysis and Forecast Report 2030

Market Overview
CRI has released a report titled Pulmonary Arterial Hypertension Market – Analysis of Market Size, Share & Trends for 2014 – 2020 and Forecasts to 2031. The market is anticipated to reach at USD 7.0 billion in 2021 and is estimated to expand at a compound annual growth rate (CAGR) of 5.2% from 2022 to 2030. . According to the report, emphasizes on the detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demands, industry and CAGR in order to provide a comprehensive outlook of the global market

Pulmonary Arterial Hypertension Market Market: Key Players

United Therapeutics Corporation

Bayer

Gilead Sciences, Inc.

Johnson & Johnson

Viatris Inc.

GlaxoSmithKline

Sandoz Inc. (Novartis)

Lupin Pharmaceuticals, Inc.

Sun Pharmaceutical Industries, Inc.

Teva Pharmaceutical Industries Ltd.

Segmentation
Research has segmented the global pulmonary arterial hypertension market report on the basis of drug class, type, route of administration, and region:

Drug Class Outlook (Revenue, USD Million, 2017 – 2030)

Endothelin Receptor Antagonists (ERAs)

PDE-5 Inhibitors

Prostacyclin and Prostacyclin Analogs

SGC Stimulators

Type Outlook (Revenue, USD Million, 2017 – 2030)

Branded

Generics

Route of Administration Outlook (Revenue, USD Million, 2017 – 2030)

Oral

Intravenous/ subcutaneous

Inhalational

Pulmonary Arterial Hypertension Market Market Dynamics
Pulmonary Arterial Hypertension Market Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
COVID-19 pre and post business impact analysis
Detailed overview of the parent market
Changing market dynamics in the industry
In-depth market segmentation
What is the Pulmonary Arterial Hypertension Market Market growth?
Which segment accounted for the largest Pulmonary Arterial Hypertension Market Market share?
Who are the key players in the Griddles Market?
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint
Note: Although care has been taken to maintain the highest levels of accuracy in CRI’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Related Reports: Global Multiplex Biomarker Imaging Market (2018 – 2023)

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Executive Summary
2. Pulmonary Arterial Hypertension Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Pulmonary Arterial Hypertension Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Pulmonary Arterial Hypertension Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Pulmonary Arterial Hypertension Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
Company Profile

United Therapeutics Corporation

Bayer

Gilead Sciences, Inc.

Johnson & Johnson

Viatris Inc.

GlaxoSmithKline

Sandoz Inc. (Novartis)

Lupin Pharmaceuticals, Inc.

Sun Pharmaceutical Industries, Inc.

Teva Pharmaceutical Industries Ltd.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

Reviews

There are no reviews yet.

Be the first to review “Global Pulmonary Arterial Hypertension Market Analysis and Forecast Report 2030”